Dashboard
Manage Tickers

CRNXCrinetics Pharmaceuticals, ...

Nasdaq crinetics.com


$ 46.62 $ -0.85 (-1.79 %)    

Tuesday, 28-May-2024 14:28:11 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ -0.69 (-0.15 %)
DIA $ 398.57 $ -2.28 (-0.58 %)
SPY $ 530.36 $ -2.05 (-0.39 %)
TLT $ 91.26 $ -1.19 (-1.31 %)
GLD $ 225.37 $ 0.01 (0 %)
$ 47.47
$ 48.42
$ 46.51 x 182
$ 46.71 x 103
$ 46.51 - $ 48.42
$ 15.76 - $ 53.70
550,435
na
2.56B
$ 0.89
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-28-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-30-2022 12-31-2021 10-K
11 11-05-2021 09-30-2021 10-Q
12 08-10-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-30-2021 12-31-2020 10-K
15 11-06-2020 09-30-2020 10-Q
16 08-07-2020 06-30-2020 10-Q
17 05-08-2020 03-31-2020 10-Q
18 03-09-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-13-2019 06-30-2019 10-Q
21 05-13-2019 03-31-2019 10-Q
22 03-13-2019 12-31-2018 10-K
23 11-13-2018 09-30-2018 10-Q
24 08-30-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

baird-maintains-outperform-on-crinetics-pharmaceuticals-raises-price-target-to-62
Baird Maintains Outperform on Crinetics Ph...
05/23/2024 16:37:36

Baird analyst Brian Skorney maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform and raises the price target ...

morgan-stanley-maintains-overweight-on-crinetics-pharmaceuticals-raises-price-target-to-70
Morgan Stanley Maintains Overweight on Cri...
05/23/2024 15:23:26

Morgan Stanley analyst Jeffrey Hung maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and raises the price...

hc-wainwright--co-reiterates-buy-on-crinetics-pharmaceuticals-maintains-60-price-target
HC Wainwright & Co. Reiterates Buy on Crin...
05/23/2024 11:15:39

HC Wainwright & Co. analyst Douglas Tsao reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and maintains $60...

analog-devices-posts-strong-earnings-joins-tjx-williams-sonoma-and-other-big-stocks-moving-higher-on-wednesday
Analog Devices Posts Strong Earnings, Join...
05/22/2024 14:22:53

Core News & Articles
Market-Moving News for May 22nd
05/22/2024 12:34:04

CRNX: 11% | Crinetics Pharmaceuticals shares are trading higher after the company announced the early release of ENDO 2024 late...

crinetics-pharmaceuticals-announces-endo-2024-late-breaking-abstracts-were-released-earlier-than-the-previously-announced-embargoed-date-more-fulsome-data-set-will-be-shared-within-the-poster-presentations-scheduled-to-be-presented-on-june-3-2024
Crinetics Pharmaceuticals Announces ENDO 2...
05/22/2024 12:02:50

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) a clinical stage pharmaceutical company focused on the discovery, development and...

18-analysts-have-this-to-say-about-crinetics-pharmaceuticals
18 Analysts Have This To Say About Crineti...
05/14/2024 16:00:29

cantor-fitzgerald-reiterates-overweight-on-crinetics-pharmaceuticals-maintains-65-price-target
Cantor Fitzgerald Reiterates Overweight on...
05/14/2024 12:45:28

Cantor Fitzgerald analyst Josh Schimmer reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and maintains $...

hc-wainwright--co-reiterates-buy-on-crinetics-pharmaceuticals-maintains-60-price-target
HC Wainwright & Co. Reiterates Buy on Crin...
05/10/2024 19:40:30

HC Wainwright & Co. analyst Douglas Tsao reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and maintains $60...

jmp-securities-reiterates-market-outperform-on-crinetics-pharmaceuticals-maintains-80-price-target
JMP Securities Reiterates Market Outperfor...
05/10/2024 16:45:04

JMP Securities analyst Jonathan Wolleben reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and mai...

crinetics-pharmaceuticals-q1-2024-gaap-eps-093-misses-081-estimate-sales-640000k-beat-255556k-estimate
Crinetics Pharmaceuticals Q1 2024 GAAP EPS...
05/09/2024 20:40:40

Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(0.93) per share which missed the analyst consensus estim...

crinetics-pharmaceuticals-to-present-advancements-from-atumelnant-and-paltusotine-development-programs-at-endo-2024-june-1-4-2024
Crinetics Pharmaceuticals To Present Advan...
05/08/2024 21:44:45

Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings fr...

piper-sandler-maintains-overweight-on-crinetics-pharmaceuticals-raises-price-target-to-97
Piper Sandler Maintains Overweight on Crin...
05/07/2024 11:08:29

Piper Sandler analyst Yasmeen Rahimi maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and raises the pric...

live-on-cnbc-stempoint-capital-cio-michelle-ross-mentions-crinetics-pharmaceuticals-as-a-glp-1-adjacent-play-during-halftime-segment-opportunities-in-biotech-calling-it-her-best-biotech-idea
Live On CNBC, StemPoint Capital CIO Michel...
04/03/2024 16:40:31

jmp-securities-reiterates-market-outperform-on-crinetics-pharmaceuticals-maintains-80-price-target
JMP Securities Reiterates Market Outperfor...
03/28/2024 14:41:23

JMP Securities analyst Jonathan Wolleben reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and mai...

oppenheimer-maintains-outperform-on-crinetics-pharmaceuticals-raises-price-target-to-55
Oppenheimer Maintains Outperform on Crinet...
03/20/2024 15:52:20

Oppenheimer analyst Leland Gershell maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform and raises the price...

jmp-securities-maintains-market-outperform-on-crinetics-pharmaceuticals-raises-price-target-to-80
JMP Securities Maintains Market Outperform...
03/20/2024 13:35:41

JMP Securities analyst Jonathan Wolleben maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and rais...

hc-wainwright--co-maintains-buy-on-crinetics-pharmaceuticals-raises-price-target-to-60
HC Wainwright & Co. Maintains Buy on Crine...
03/20/2024 10:35:16

HC Wainwright & Co. analyst Douglas Tsao maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and raises the pri...

jonestrading-maintains-buy-on-crinetics-pharmaceuticals-raises-price-target-to-56
JonesTrading Maintains Buy on Crinetics Ph...
03/20/2024 10:08:30

JonesTrading analyst Lina Kaminski maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and raises the price target ...

crinetics-pharmaceuticals-inc-files-for-resale-of-up-to-833m-shares-by-the-selling-stockholders
Crinetics Pharmaceuticals Inc Files For Re...
03/19/2024 20:43:13

- SEC Filing

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION